Company:  CRINETICS PHARMACEUTICALS ... (CRNX)
Form Type:  S-3
Filing Date:  8/13/2019 
CIK:  0001658247 
Address:  10222 BARNES CANYON ROAD, BLDG. #2 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-450-6464 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$18.73  
Change: 
0.67 (3.71%)  
Trade Time: 
Aug 16  
Market Cap: 
$453.27M
Trade CRNX now with 

© 2019  
Description of Business
We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Endocrine pathways function to maintain homeostasis and commonly use peptide hormones acting through G protein coupled receptors, or GPCRs, to regulate many aspects of physiology including growth, energy, metabolism, gastrointestinal function and stress responses. We have assembled a seasoned team with extensive expertise in drug discovery and development in endocrine GPCRs and built a highly productive drug discovery organization. We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of rare endocrine diseases where treatment options have significant efficacy, safety and/or tolerability limitations.
Register and access this filing in:     
  FORM S-3
    CALCULATION OF REGISTRATION FEE
    EXPLANATORY NOTE
    Subject to Completion, dated August 13, 2019.
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS
    WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
    RISK FACTORS
    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    DIVIDEND POLICY
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
      Indemnification
    DESCRIPTION OF DEBT SECURITIES
    No Personal Liability of Directors, Officers, Employees or ...
    DESCRIPTION OF WARRANTS
    DESCRIPTION OF UNITS
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    EXPERTS
    THE OFFERING
    RISK FACTORS
    USE OF PROCEEDS
    DILUTION
    PART II
      Item 14. Other Expenses of Issuance and Distribution
      Item 15. Indemnification of Directors and Officers
      Item 16. Exhibits
      Item 17. Undertakings
    SIGNATURES
    POWER OF ATTORNEY
  EXHIBIT 1.2
  EXHIBIT 4.4
  EXHIBIT 5.1
  EXHIBIT 5.2
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm